| Record ID | marc_columbia/Columbia-extract-20221130-009.mrc:52662655:1891 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-009.mrc:52662655:1891?format=raw |
LEADER: 01891fam a2200397 a 4500
001 4049409
005 20221027024441.0
008 950419t19951995nyu b 001 0 eng
010 $a 95009025
020 $a0312128738
035 $a(OCoLC)32468449
035 $a(OCoLC)ocm32468449
035 $9AKZ6677HS
035 $a(NNC)4049409
035 $a4049409
040 $aDLC$cDLC$dNNC-M$dOrLoB-B
043 $an-us---$ae-uk---
050 00 $aRM301.27$b.A27 1995
082 00 $a615/.19$220
100 1 $aAbraham, John.$0http://id.loc.gov/authorities/names/n2016038291
245 10 $aScience, politics, and the pharmaceutical industry :$bcontroversy and bias in drug regulation /$cJohn Abraham.
260 $aNew York :$bSt. Martin's Press,$c[1995], ©1995.
300 $axi, 308 pages ;$c23 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
504 $aIncludes bibliographical references and index.
505 00 $g1.$tBias in science and regulation --$g2.$tPartial progress? The development of American and British drug regulation --$g3.$tNaprosyn - reconstructing data --$g4.$tOpren/Oraflex - the making of a drug disaster --$g5.$tFeldene - the closure of technical dispute --$g6.$tZomax - the persistence of data --$g7.$tSuprol - anything goes? --$g8.$tConclusions and policy implications.
650 0 $aDrugs$xTesting$xGovernment policy$zUnited States.
650 0 $aDrugs$xTesting$xGovernment policy$zGreat Britain.
650 0 $aDrugs$xToxicology$vCase studies.
650 2 $aPharmaceutical Preparations.$0https://id.nlm.nih.gov/mesh/D004364
650 2 $aToxicology.$0https://id.nlm.nih.gov/mesh/D014116
651 2 $aUnited States.$0https://id.nlm.nih.gov/mesh/D014481
651 2 $aUnited Kingdom.$0https://id.nlm.nih.gov/mesh/D006113
655 2 $aCase Reports.$0https://id.nlm.nih.gov/mesh/D002363
852 00 $boff,hsl$hRM301.27$i.A27 1995